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Abstract Peroxisome proliferator-activated receptors (PPARs)
are nuclear receptors, which heterodimerize with the retinoid X
receptor and bind to peroxisome proliferator response elements
in the promoters of regulated genes. Despite the wealth of
information available on the function of PPARK and PPARQ,
relatively little is known about the most widely expressed PPAR
subtype, PPARN. Here we show that treatment of insulin
resistant db/db mice with the PPARN agonist L-165 041, at
doses that had no effect on either glucose or triglycerides, raised
total plasma cholesterol concentrations. The increased cholester-
ol was primarily associated with high density lipoprotein (HDL)
particles, as shown by fast protein liquid chromatography
analysis. These data were corroborated by the chemical analysis
of the lipoproteins isolated by ultracentrifugation, demonstrating
that treatment with L-165 041 produced an increase in circulat-
ing HDL without major changes in very low or low density
lipoproteins. White adipose tissue lipoprotein lipase activity was
reduced following treatment with the PPARN ligand, but was
increased by a PPARQ agonist. These data suggest both that
PPARN is involved in the regulation of cholesterol metabolism in
db/db mice and that PPARN ligands could potentially have
therapeutic value.
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1. Introduction
Three mammalian peroxisome proliferator-activated recep-
tors (PPARK, PPARN and PPARQ) are known (for review see
[1,2]). PPARK, the ¢rst PPAR identi¢ed [3], regulates the ex-
pression of genes involved in lipid metabolism. PPARK ago-
nists, such as the ¢brates, are used to treat hyperlipidemia
(reviewed in [1,4]). PPARQ is an important regulator of adipo-
genesis, lipid metabolism and glucose homeostasis (reviewed
in [5]). The thiazolidinedione (TZD) PPARQ agonists, such as
rosiglitazone or pioglitazone, are used as insulin sensitizers in
the treatment of non-insulin-dependent diabetes mellitus [6^9]
(for review see [10]). In contrast to PPARK and PPARQ, rel-
atively little is known about the function of the most ubiqui-
tously expressed PPAR, PPARN [11^13]. PPARN is also
known as NUC-1 [11] or FAAR [13] and it is presently un-
clear whether PPARL in Xenopus [14] is its functional homo-
log.
The absence of data relating to the physiological role of
PPARN can be explained on the one hand by the lack of
speci¢c high a⁄nity ligands which can be used as physiolog-
ical probes and also by the absence of animal models carrying
mutations in the PPARN gene. We recently described a ligand
(L-165 041) that can be used to begin to explore the physio-
logical role of PPARN [15]. Recently, two papers described
potential roles for PPARN. First, Lim et al. [16], using
L-165 041 and other techniques, have shown that PPARN is
involved in the regulation of embryo implantation in the
mouse. Second, PPARN has recently been shown to be an
APC-regulated target gene [17].
2. Materials and methods
2.1. Materials
The TZD AD-5075 (5-[4-[2-(5-methyl-2-phenyl-4-oxazoly)-2-hy-
droxyethoxy]benzyl]-2,4-thiazolidinedione), and L-165 041 (4-[3-[2-
propyl-3-hydroxy-4-acetyl]phenoxy]propyloxyphenoxy acetic acid)
were kindly provided by Gerard Kieczykowski, Philip Eskola, Joseph
F. Leone, Mark S. Levorse and Peter A. Cicala (Merck Research
Laboratories, Rahway, NJ, USA).
2.2. In vivo studies
Male db/db mice (10^11 week old C57BLKS/J-m +/+Leprdb, Jack-
son Laboratory, Bar Harbor, ME, USA) were housed 3^5/cage and
allowed ad libitum access to ground Purina rodent chow and water.
Lean animals were age-matched heterozygous mice maintained in the
same manner. The animals, and their food, were weighed every 2 days
and were dosed daily by gavage with vehicle (0.5% carboxymethylcel-
lulose) þ PPAR agonists at the indicated doses. Drug suspensions were
prepared daily. Plasma glucose, triglyceride and cholesterol concen-
trations were determined from blood obtained by tail bleeds into
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heparinized capillaries at 3^5 day intervals during the study. At the
end of the study animals were fasted overnight and serum was pre-
pared from the blood of animals that were exsanguinated by heart
puncture. Epididymal white adipose tissue (WAT) was frozen in liquid
nitrogen following exsanguination. All animal experiments were ap-
proved by the Institutional Animal Care and Use Committee.
2.3. Biochemical analysis
Glucose, triglyceride and/or cholesterol determinations were per-
formed on either an Alpkem RFA/2 320 Micro-Continuous Flow
Analyzer (Astoria-Paci¢c International, Clackamas, OR) or a Boehr-
inger Mannheim Hitachi 911 automatic analyzer (Boehringer Mann-
heim, Indianapolis, IN, USA) using heparinized plasma diluted 1:6
(v/v) with normal saline and commercially available reagents (Boehr-
inger Mannheim). Lipoprotein cholesterol pro¢les were obtained by
fast protein liquid chromatography (FPLC) size fractionation of lipo-
proteins. Pooled mouse serum samples (150 or 200 Wl) were injected
onto a Superose 6 HR 10/30 prepacked column (Pharmacia, Uppsala,
Sweden) and eluted at a constant £ow rate of 0.2 ml/min with 10 mM
phosphate-bu¡ered saline, pH 7.2. The e¥uent was collected in
0.27 ml fractions and cholesterol and triglyceride concentrations
were determined in 0.1 ml of each fraction. For the analysis of lipo-
protein composition, the lipoprotein fractions were isolated from se-
rum according to their hydrated density by sequential ultracentrifu-
gation and analyzed for protein, cholesterol, triglyceride and
phospholipid content as described [18]. The corresponding density
ranges were as follows: very low density lipoproteins (VLDL),
d6 1.006; low density lipoproteins (LDL), 1.0066 d6 1.063 and
high density lipoproteins (HDL), 1.0636 d6 1.21.
2.4. Lipoprotein lipase (LPL) activity
LPL activity was measured in epididymal WAT extracts according
to the procedure of Ramirez et al. [19]. One unit of enzyme activity
was de¢ned as the amount of enzyme that released 1 Wmol oleate/min
at 25‡C.
3. Results and discussion
We recently described a synthetic PPAR ligand, L-165 041
that binds to both PPARN and PPARQ ; while L-165 041 binds
to and activates both PPARN and PPARQ, it has a substan-
tially lower a⁄nity for PPARQ than PPARN (Table 1) [15].
The compound does not activate mouse PPARK. To charac-
terize the e¡ects of PPARN activation we compared the e¡ects
of L-165 041 treatment to those of the TZD AD-5075, a se-
lective PPARQ agonist, in the insulin-resistant db/db mouse, a
commonly used animal model for metabolic studies. As a
result of a defective leptin receptor, db/db mice are obese,
hyperglycemic and hypertriglyceridemic (for review see [20]).
PPARQ binding a⁄nity has been shown to be correlated with
the hypoglycemic activity of both TZD and non-TZD PPARQ
agonists in db/db mice [8,9,15]. Ten week old male db/db mice
were dosed daily by gavage with the Q selective agonist AD-
5075 (2 mg/kg body weight/day (mg/kg)), or the PPARN ago-
nist L-165 041 (10 or 30 mg/kg) for 31 days. AD-5075 reduced
plasma glucose and triglyceride concentrations essentially to
those of age-matched lean mice. At both doses, L-165 041
produced little e¡ect on either plasma glucose or triglycerides
(Fig. 1a,b) and [15]. Higher doses of L-165 041 (100 mg/kg)
will lower both glucose and triglycerides in db/db mice, as
expected based upon its binding a⁄nity for PPARQ, not
PPARN (data not shown).
In contrast to the e¡ects on glucose or triglycerides, the
determination of total plasma cholesterol concentrations
showed that the PPARN agonist produced signi¢cant, dose-
dependent increases in total plasma cholesterol (Fig. 2a). The
PPARQ agonist signi¢cantly lowered plasma cholesterol in db/
db mice (Fig. 2a). We next examined the size distribution of
cholesterol-containing lipoprotein particles in a single pool of
serum from the animals treated with either 10 or 30 mg/kg of
L-165 041. Each pool was fractionated by FPLC and the dis-
tribution of cholesterol is shown in Fig. 3a. Almost all of the
cholesterol is contained in small, dense particles that contain
little triglyceride (data not shown) and are presumably HDL
particles. Treatment with L-165 041 produced a dose-depen-
dent increase in HDL cholesterol. This observation is in sharp
contrast to the decrease in HDL cholesterol levels observed in
rodents after treatment with ¢brate PPARK agonists [21,22].
Both doses of L-165 041 produced an equivalent, small in-
crease in LDL cholesterol.
Table 1
PPAR ligands
*Binding based on [5].
Fig. 1. Mean ( þ S.E.M.) plasma glucose (a) and triglyceride (b) con-
centrations of db/db mice treated with the indicated compounds; ve-
hicle (b), 2 mg/kg body weight AD-5075 (R), 10 or 30 mg/kg body
weight L-165 041 (E,F). Values for age-matched lean mice dosed
with vehicle (-).
Fig. 2. a: Plasma cholesterol values (mean þ S.E.M.) from db/db or
lean mice treated for 31 days, as indicated. Asterisks indicate values
statistically di¡erent from db/db control (Student’s t-test,
**P6 0.01). b: LPL activity in epididymal WAT obtained from db/
db or lean animals treated for 31 days. Asterisks indicate values sta-
tistically di¡erent from db/db control (Student’s t-test, **P6 0.01;
***P6 0.001).
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In a more detailed experiment we examined both the dis-
tribution of cholesterol-containing lipoprotein particles by
FPLC and determined the chemical composition of lipopro-
teins, isolated by ultracentrifugation according to their hy-
drated density. We ¢rst compared the distribution of choles-
terol-containing lipoproteins by FPLC analysis of pooled
serum from db/db mice dosed with AD-5075 (2 mg/kg) or
L-165 041 (30 mg/kg) for 14 days (Fig. 3b). Treatment with
AD-5075 reduced the HDL cholesterol peak and produced a
dramatic increase in LDL. In contrast, treatment with L-
165 041 produced an increase in HDL cholesterol with little
change in the LDL fraction. We determined the chemical
composition of lipoproteins isolated by ultracentrifugation
(Fig. 4). None of the treatments altered the composition of
HDL particles, suggesting that L-165 041 raised HDL choles-
terol by increasing the number of HDL particles. This re£ects
a true increase in the HDL/(VLDL+LDL) ratio. AD-5075
treatment, however, dramatically altered the composition of
both VLDL and LDL particles, producing a decrease in the
triglyceride content of VLDL and generating a cholesterol-
enriched LDL fraction. This observation was consistent with
the increase in LDL levels observed following FPLC fraction-
ation of lipoprotein particles (Fig. 3b) and could be the con-
sequence of enhanced lipolysis (Fig. 2b).
Since PPARQ agonists have been shown to increase WAT
LPL activity, via a direct transcriptional e¡ect on the LPL
promoter [23], we wanted to determine whether a change in
LPL activity could explain some of the changes in either lipo-
protein distribution or composition described above. Consis-
tent with our previous observation [23], the PPARQ agonist
AD-5075 signi¢cantly increased total WAT LPL activity in
tissues taken from db/db mice dosed for 31 days (Fig. 2b).
This increased LPL activity most likely contributes to the
changes in lipoprotein characteristics, observed in an inde-
pendent experiment, after AD-5075 treatment (Fig. 3b). On
the other hand, both the 10 and 30 mg/kg doses of L-165 041
signi¢cantly lowered total LPL activity. These data strongly
suggest di¡erential regulation of LPL activity by activation of
PPARN or PPARQ.
We have shown that doses of a PPARN agonist (L-165 041)
that produce signi¢cant increases in plasma cholesterol do not
alter plasma glucose or triglycerides in db/db mice. In addi-
tion, this increase in cholesterol is associated with HDL cho-
lesterol and an increase in the ratio of HDL to non-HDL
cholesterol. While the increase in HDL produced by PPARN
agonists is relatively small, modest HDL-raising e¡ects can be
clinically important. The most widely used drugs for HDL-
raising in man are the ¢brates, although they lower HDL in
rodents [21,22]. In man the ¢brates raise HDL 15^20% [24,25]
and have been shown to decrease coronary heart disease [25].
In contrast, PPARQ agonists lower plasma glucose, triglycer-
ides, cholesterol and apo A-I in rodents. Furthermore PPARQ,
but not PPARN, agonists induce a dramatic increase in LDL
particles, caused by an LPL-mediated lipolysis of triglyceride-
rich lipoproteins. Combined with our previous observations of
a dramatic HDL lowering e¡ect of PPARK agonists [21,22],
the e¡ects observed in the current study concerning PPARN
and PPARQ activation on lipid parameters suggest a distinct
pharmacology associated with activation of the respective re-
ceptors.
The exact molecular mechanisms by which PPARN activa-
tion achieves its e¡ects are unclear. Future experiments are
designed to determine speci¢cally which metabolic pathways
are being directly e¡ected by PPARN activation. In this con-
text it is interesting to note that all PPARs seem to control
pivotal aspects of intracellular lipid handling; whereas PPARK
controls fatty acid L-oxidation, PPARQ seems to favor lipid
storage. Through these activities both PPARK and Q have
important e¡ects on extracellular lipid homeostasis [1]. Our
data suggest that PPARN also ¢ts this paradigm, since its
activation markedly a¡ects lipid homeostasis. Previous studies
suggested that PPARN activation could counteract the activity
of other PPARs, such as PPARK [26]. Although this could
explain the L-165 041-mediated inhibition of LPL activity,
which is normally stimulated by PPARK and PPARQ activa-
tion [23], multiple other direct e¡ects could also be invoked.
Cholesterol metabolism is regulated di¡erently in man and
rodents. Therefore, one must exercise caution in any extrap-
olation from the current data to the human situation. In ad-
dition, the current observations are in db/db mice that have
alterations in lipid metabolism. Additional experiments should
include examination of L-165 041-induced e¡ects in non-dia-
betic animals. Nevertheless, these observations suggest that
PPARN plays a role in lipid metabolism in db/db mice and
suggest that PPARN ligands could be novel therapeutic agents,
if our observations in db/db mice are recapitulated in non-
diabetic rodents and ultimately in man.
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Fig. 4. Mass composition of lipoproteins (VLDL, d6 1.006; LDL,
1.0066 d6 1.063; HDL, 1.0636 d6 1.21) from serum of db/db
mice treated with vehicle, 2 mg/kg body weight AD-5075 or 30 mg/
kg body weight L-165 041 for 14 days (same experiment as Fig. 3b).
Fig. 3. a: Serum cholesterol distribution in pooled samples from db/
db mice treated for 31 days with vehicle, 10 or 30 mg/kg body
weight L-165 041 after gel ¢ltration chromatography. b: Serum cho-
lesterol distribution in pooled samples from db/db mice treated for
14 days with vehicle, 2 mg/kg body weight AD-5075 or 30 mg/kg
body weight L-165 041 after gel ¢ltration chromatography. Panels
(a) and (b) are from independent experiments using di¡erent sets of
db/db mice.
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